Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments
- DOI
- 10.1177/20552173251390649
- Published
- 2025-10
- Container
- Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Publisher
- SAGE Publications
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1177/20552173251390649,
title = {Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments},
author = {William Z. Lin and Jaimie J. Lee and Anibal Chertcoff and Helen Tremlett and John L. K. Kramer},
year = {2025},
journal = {Multiple Sclerosis Journal – Experimental, Translational and Clinical},
doi = {10.1177/20552173251390649},
url = {https://doi.org/10.1177/20552173251390649}
}RIS
TY - JOUR TI - Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments AU - William Z. Lin AU - Jaimie J. Lee AU - Anibal Chertcoff AU - Helen Tremlett AU - John L. K. Kramer PY - 2025 JO - Multiple Sclerosis Journal – Experimental, Translational and Clinical DO - 10.1177/20552173251390649 UR - https://doi.org/10.1177/20552173251390649 ER -
APA
Lin, W. Z., Lee, J. J., Chertcoff, A., Tremlett, H., & Kramer, J. L. K. (2025). Safety reporting quality in multiple sclerosis clinical trials: A review of phase III clinical trials included in FDA approval of disease-modifying treatments. Multiple Sclerosis Journal – Experimental, Translational and Clinical. https://doi.org/10.1177/20552173251390649
Source records
- crossref · retrieved 2026-09-25T19:28:37.689Z